Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Retained Earnings (2020 - 2025)

Relay Therapeutics (RLAY) has disclosed Retained Earnings for 6 consecutive years, with -$2.0 billion as the latest value for Q4 2025.

  • On a quarterly basis, Retained Earnings fell 15.06% to -$2.0 billion in Q4 2025 year-over-year; TTM through Dec 2025 was -$2.0 billion, a 15.06% decrease, with the full-year FY2025 number at -$2.0 billion, down 15.06% from a year prior.
  • Retained Earnings was -$2.0 billion for Q4 2025 at Relay Therapeutics, down from $493000.0 in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $2.5 million in Q3 2024 to a low of -$2.0 billion in Q4 2025.
  • A 5-year average of -$806.8 million and a median of -$799.1 million in 2021 define the central range for Retained Earnings.
  • Peak YoY movement for Retained Earnings: tumbled 9911100.0% in 2022, then surged 100.19% in 2024.
  • Relay Therapeutics' Retained Earnings stood at -$768.1 million in 2021, then surged by 98.64% to -$10.4 million in 2022, then soared by 98.12% to -$196000.0 in 2023, then plummeted by 886782.65% to -$1.7 billion in 2024, then decreased by 15.06% to -$2.0 billion in 2025.
  • Per Business Quant, the three most recent readings for RLAY's Retained Earnings are -$2.0 billion (Q4 2025), $493000.0 (Q3 2025), and -$1.9 billion (Q2 2025).